BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18684088)

  • 21. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
    Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
    J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
    Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.
    Valenta A; Roschger P; Fratzl-Zelman N; Kostenuik PJ; Dunstan CR; Fratzl P; Klaushofer K
    Bone; 2005 Jul; 37(1):87-95. PubMed ID: 15869920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model.
    Lane NE; Kimmel DB; Nilsson MH; Cohen FE; Newton S; Nissenson RA; Strewler GJ
    J Bone Miner Res; 1996 May; 11(5):614-25. PubMed ID: 9157776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
    Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
    J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.
    Lane NE; Thompson JM; Strewler GJ; Kinney JH
    J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
    Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
    J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys.
    Brommage R; Hotchkiss CE; Lees CJ; Stancill MW; Hock JM; Jerome CP
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3757-63. PubMed ID: 10523026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH.
    Sato M; Vahle J; Schmidt A; Westmore M; Smith S; Rowley E; Ma LY
    Endocrinology; 2002 Sep; 143(9):3230-42. PubMed ID: 12193534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat.
    Lane NE; Haupt D; Kimmel DB; Modin G; Kinney JH
    J Bone Miner Res; 1999 Feb; 14(2):206-14. PubMed ID: 9933474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term changes in bone mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium restricted, and/or estrogen-deprived/-replaced rats.
    Jiang Y; Zhao J; Genant HK; Dequeker J; Geusens P
    J Bone Miner Res; 1997 May; 12(5):820-31. PubMed ID: 9144349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice.
    Wu J; Wang XX; Takasaki M; Ohta A; Higuchi M; Ishimi Y
    J Bone Miner Res; 2001 Oct; 16(10):1829-36. PubMed ID: 11585347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.
    Ma YL; Zeng QQ; Porras LL; Harvey A; Moore TL; Shelbourn TL; Dalsky GP; Wronski TJ; Aguirre JI; Bryant HU; Sato M
    Endocrinology; 2011 May; 152(5):1767-78. PubMed ID: 21343258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.